FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $15,812 | +72.0% | 3,322 | +106.0% | 0.00% | – |
| Q1 2023 | $9,194 | -97.7% | 1,613 | -96.0% | 0.00% | -100.0% |
| Q4 2022 | $404,205 | -92.7% | 40,060 | -83.9% | 0.00% | -90.0% |
| Q3 2022 | $5,571,000 | +3.0% | 248,619 | +13.9% | 0.01% | +11.1% |
| Q2 2022 | $5,409,000 | -41.9% | 218,302 | -9.2% | 0.01% | -25.0% |
| Q1 2022 | $9,317,000 | -34.7% | 240,327 | -1.4% | 0.01% | -25.0% |
| Q4 2021 | $14,267,000 | – | 243,847 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |